US Bancorp’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,000
| Closed | -$19K | – | 3819 |
|
|
2019
Q3 | $19K | Buy |
1,000
+862
| +625% | +$9.86K | ﹤0.01% | 2875 |
|
|
2019
Q2 | $2K | Hold |
138
| – | – | ﹤0.01% | 3515 |
|
|
2019
Q1 | $2K | Sell |
138
-1,673
| -92% | -$21.7K | ﹤0.01% | 3464 |
|
|
2018
Q4 | $19K | Hold |
1,811
| – | – | ﹤0.01% | 2839 |
|
|
2018
Q3 | $30K | Sell |
1,811
-790
| -30% | -$14.3K | ﹤0.01% | 2790 |
|
|
2018
Q2 | $41K | Hold |
2,601
| – | – | ﹤0.01% | 2667 |
|
|
2018
Q1 | $33K | Hold |
2,601
| – | – | ﹤0.01% | 2793 |
|
|
2017
Q4 | $30K | Buy |
2,601
+2,463
| +1,785% | +$27.5K | ﹤0.01% | 2796 |
|
|
2017
Q3 | $2K | Buy |
+138
| New | +$1.44K | ﹤0.01% | 3464 |
|
|
2017
Q2 | – | Sell |
-47
| Closed | -$1K | – | 3664 |
|
|
2017
Q1 | $1K | Buy |
47
+5
| +12% | +$111 | ﹤0.01% | 3508 |
|
|
2016
Q4 | $1K | Buy |
+42
| New | +$1.09K | ﹤0.01% | 3495 |
|
|
2016
Q3 | – | Sell |
-871
| Closed | -$22K | – | 3676 |
|
|
2016
Q2 | $22K | Buy |
+871
| New | +$23.6K | ﹤0.01% | 2767 |
|
|
2016
Q1 | – | Sell |
-150
| Closed | -$5K | – | 3719 |
|
|
2015
Q4 | $5K | Buy |
+150
| New | +$5.07K | ﹤0.01% | 3259 |
|
US Bancorp's ALDR Position: Q4 2019 in Review
US Bancorp sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,000 shares — an estimated $19K sold.
US Bancorp first reported a position in ALDR in Q4 2015 and held it in 13 quarters. The position peaked at $41K in Q2 2018. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- US Bancorp reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- US Bancorp sold 1,000 Alder Biopharmaceuticals shares in Q4 2019, an estimated $19K.
- US Bancorp first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 13 quarters.
- US Bancorp's Alder Biopharmaceuticals position peaked at $41K in Q2 2018.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on US Bancorp's 13F filing for Q4 2019, filed 4 Feb 2020.